ArticleAmerican journal of translational research2025
PLXND1 from the Plexins family is a prognostic factor promoting colon cancer invasion and metastasis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A machine learning-based predictive model for radiosensitivity in nasopharyngeal carcinoma utilizing serum proteomics.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo elucidate the expression profile, immune infiltration, prognostic value, and role of Plexins in Colonic Adenocarcinoma (COAD).
methodsThe levels of the Plexins family members in COAD were verified, and their effect on clinical characteristics, immune infiltration, and prognosis were explored by The Cancer Genome Atlas (TCGA), Expression Atlas, and Human Protein Atlas (HPA) databases. The core molecule of Plexins, PLXND1, was screened and validated in COAD by qRT-PCR, immunohistochemistry, wound healing, transwell, immunofluorescence, western blotting, immunoprecipitation, and animal experiments.
resultsThe PLXNA1/PLXNA3/PLXNA4/PLXNB1/PLXND1 levels were increased in COAD samples, whereas the levels of PLXNA2/PLXNB3/PLXNC1 were reduced. High PLXNA3/PLXNA4/PLXNB3/PLXND1 levels were related to the higher lymph node stage of COAD patients. Most Plexin levels were prominently associated with the infiltration of T cell regulators, macrophage M0, and eosinophils in COAD samples. High PLXNA3/PLXNB3/PLXND1 levels were interrelated with poor overall survival of COAD patients, and PLXND1 was a novel independent prognostic indicator. Furthermore, the PLXND1-associated differential molecular regulatory networks were analyzed, and the expression of PLXND1 was markedly increased in COAD tissues and lymph node-positive COAD patients. Mechanistically, PLXND1 promoted COAD cell invasion, metastasis, and epithelial-mesenchymal transition (EMT) ability by binding and modulating Notch3 signaling.
conclusionsData mining revealed the crucial roles of the Plexin family in COAD, especially in clinical indicators, immune infiltration, and prognosis of COAD patients. PLXND1, as an independent prognostic biomarker, enabled COAD cell invasion, metastasis and EMT by binding and modulating Notch3 signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.